Censa Pharmaceuticals focuses on developing treatments for rare metabolic disorders. Censa was acquired by PTC Therapeutics (NASDAQ: PTCT) in 2020.
Arkin Entry Stage
Pre Clinical
Status
M&A
Location
Boston, MA
Let’s get in touch!
